Newormics was selected for the NIH I-Corps April-June 2019 cohort. Over the course of the I-Corps program, the team had conversations with over 100 stakeholders in the field. This helped the company gather vital market research to understand the needs and pain points of potential customers, and improve Newormics product lines
The program finale was held in Washington, DC where Newormics presented for the rest of the I-Corps cohort.
Dr. Sudip Mondal has a Ph.D. in Physics and several years of postdoctoral research experience in neuroscience and microfluidics-based screening tools. He has developed several technologies that have translated to the market. One of his recent works at The University of Texas at Austin involved a high-throughput screening platform with C. elegans model systems, which is commercialized by vivoVerse. As a Director of Science, Sudip is responsible for developing new technologies and innovative assays to increase the vivoVerse product & service portfolio.
A professor with dual appointments in Mechanical Engineering and Biomedical Engineering at The University of Texas at Austin, Dr Ben-Yakar’s research focuses on the creation of imaging technologies and novel laser surgery with high precision. Educated at Stanford and the Technion in Israel, with post-doctoral study at Harvard, and using her NIH Director’s Transformative Research Award, Dr Ben-Yakar began the research that has culminated in the launch of vivoVerse (formerly Newormics)
Evan Hegarty, co-founder, received his M.S. in Mechanical Engineering at The University of Texas at Austin while developing the technology and IP that lead to the launch of Newormics, LLC, now vivoVerse. As the Director of Manufacturing and Product development, and Principal Investigator of NIH SBIR grants at vivoVerse, Evan is responsible for development of all chip and system designs, creating production schedules, optimizing production methods, managing team members, identifying customer needs, developing future products, and reinforcing GLP and GMP.
Dr. Lento is a serial COO/VPO executive for life science startups with broad skills in pharmaceuticals, medical devices, and diagnostics. With a unique background of equal parts government, public and private sector service, Dr. Lento holds a PhD in Biochemistry and additional credentials in Drug Evaluation, Pharmaceutical Sciences, and Corporate Governance, as well as an MBA in Healthcare Administration.
Dr. Adam Laing is a molecular and cellular biologist educated at the University of Edinburgh, and leads the Research and Development activities at vivoVerse. He is responsible for testing and characterizing the new devices and imaging methods, and development of toxicology and drug screening assays in C. elegans as well as tissue organoids.
Jacob Moore completed his master’s and PhD in mechanical engineering at the University of Texas at Austin before joining the vivoVerse team. From his experimental research in the gas turbine industry, he developed a hands-on expertise in thermal/fluids systems that he is applying to chip and system designs. In addition, he is using his automated laboratory measurement experience to mature automation designs using vivoVerse technology.
Nicholas Chavez graduated with a Bachelors in Computational Biomedical Engineering from The University of Texas at Austin. After spending time as a software engineer in the tech industry, he has returned to the biotech field in the capacity of a bioimaging software engineer for vivoVerse. Here, he aids the company with the automation of data acquisition and processing as well as the development of embedded systems and full stack processes.